Aimed Alliance has released a new resource explaining recent federal reforms to pharmacy benefit managers (PBMs) under the Consolidated Appropriations Act, 2026, which require “delinking” PBM compensation from drug prices in Medicare Part D. The resource outlines how delinking reduces incentives for higher drug costs by shifting PBMs to flat service fees, while also increasing transparency and accountability. It further emphasizes that these reforms apply only to Medicare Part D and calls on states to take action by extending similar protections to state-regulated markets, where many consumers remain exposed to existing pricing and rebate-driven practices. View the delinking resource.
Last Updated on June 1, 2026 by Aimed Alliance
